BioSight
Companies
IOVANCE BIOTHERAPEUTICS, INC. logo

IOVA

NASDAQSAN CARLOS, CA
IOVANCE BIOTHERAPEUTICS, INC.

Iovance develops cell-based immunotherapies, specifically tumor infiltrating lymphocytes (TIL) therapies, for cancer treatment. The company has one FDA-approved product, Amtagvi (lifileucel), and is advancing additional TIL candidates through clinical trials while working to establish its own manufacturing facility. Iovance is a clinical and commercial-stage biotech firm focused on bringing cell therapy treatments to market.

Price history not yet available for IOVA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar